▎WuXiEdited by the Kant Content Team
On July 11, Sirius Therapeutics announced its self-developedSmall Nucleic Acid DrugsThe Phase 1 clinical trial of SRSD107 injection has recently completed dosing for all enrolled subjects. This Phase 1 clinical study was conducted simultaneously in Australia and mainland China. Preliminary research data shows that SRSD107 has good safety and tolerability, as well as expected pharmacokinetic characteristics.
Thrombosis is a blood clot that restricts blood flow within blood vessels and can occur in either arterial or venous circulation, serving as the common pathological basis for most myocardial infarctions, ischemic strokes, and venous thromboembolism (VTE).SRSD107 Injection is a double-stranded small interfering nucleic acid (siRNA) drug.It specifically targets the liver-directed coagulation factor XI (FXI) mRNA, inhibits the protein expression of FXI, and blocks the activation of the intrinsic coagulation pathway, thereby achieving anticoagulant/antithrombotic effects.FXI is a key molecule in the intrinsic coagulation pathway. An increasing number of studies have shown that inhibiting FXI can block the intrinsic coagulation pathway, offering a new and effective antithrombotic approach with a low risk of bleeding for clinical patients.Preclinical trial data shows,A single subcutaneous injection of SRSD107 can achieve nearly 100% knockdown of FXI expression, lasting up to half a year, with no bleeding observed.SRSD107 Combines Potent and Long-Lasting Effects with Good Safety, Poised to Become a New Generation of Safer Anticoagulant Drugs.Chief Medical Officer of Sirius TherapeuticsDr. Yu Peichuan"Noted: 'The successful completion of subject enrollment in the Phase 1 study, while only the first step, represents a critical milestone in the clinical development of SRSD107. The PK and PD data generated from this study will provide important scientific evidence for subsequent clinical development of the product, further optimizing its application value so that more patients can benefit sooner.'"[1]Sirius Therapeutics:New Generation siRNA-FXI Anticoagulant Completes Enrollment of All Subjects in Phase I Clinical Trial. Retrieved July 11，2024, From https://mp.weixin.qq.com/s/Zidr36a2VftHnaRLknNeGwThis article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media. For reprint authorization and other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for the purpose of information exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
